148 related articles for article (PubMed ID: 35471939)
1. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
Kettle JG; Bagal SK; Bickerton S; Bodnarchuk MS; Boyd S; Breed J; Carbajo RJ; Cassar DJ; Chakraborty A; Cosulich S; Cumming I; Davies M; Davies NL; Eatherton A; Evans L; Feron L; Fillery S; Gleave ES; Goldberg FW; Hanson L; Harlfinger S; Howard M; Howells R; Jackson A; Kemmitt P; Lamont G; Lamont S; Lewis HJ; Liu L; Niedbala MJ; Phillips C; Polanski R; Raubo P; Robb G; Robinson DM; Ross S; Sanders MG; Tonge M; Whiteley R; Wilkinson S; Yang J; Zhang W
J Med Chem; 2022 May; 65(9):6940-6952. PubMed ID: 35471939
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS
Kettle JG; Bagal SK; Barratt D; Bodnarchuk MS; Boyd S; Braybrooke E; Breed J; Cassar DJ; Cosulich S; Davies M; Davies NL; Deng C; Eatherton A; Evans L; Feron LJ; Fillery S; Gleave ES; Goldberg FW; Cortés González MA; Guerot C; Haider A; Harlfinger S; Howells R; Jackson A; Johnström P; Kemmitt PD; Koers A; Kondrashov M; Lamont GM; Lamont S; Lewis HJ; Liu L; Mylrea M; Nash S; Niedbala MJ; Peter A; Phillips C; Pike K; Raubo P; Robb GR; Ross S; Sanders MG; Schou M; Simpson I; Steward O
J Med Chem; 2023 Jul; 66(13):9147-9160. PubMed ID: 37395055
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
Kettle JG; Bagal SK; Bickerton S; Bodnarchuk MS; Breed J; Carbajo RJ; Cassar DJ; Chakraborty A; Cosulich S; Cumming I; Davies M; Eatherton A; Evans L; Feron L; Fillery S; Gleave ES; Goldberg FW; Harlfinger S; Hanson L; Howard M; Howells R; Jackson A; Kemmitt P; Kingston JK; Lamont S; Lewis HJ; Li S; Liu L; Ogg D; Phillips C; Polanski R; Robb G; Robinson D; Ross S; Smith JM; Tonge M; Whiteley R; Yang J; Zhang L; Zhao X
J Med Chem; 2020 May; 63(9):4468-4483. PubMed ID: 32023060
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
[TBL] [Abstract][Full Text] [Related]
6. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
Imaizumi T; Shimada I; Satake Y; Yamaki S; Koike T; Nigawara T; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nakayama A; Nishizono Y; Shimazaki M; Nagashima T; Kuramoto K
Bioorg Med Chem; 2024 Jan; 98():117581. PubMed ID: 38176113
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
[TBL] [Abstract][Full Text] [Related]
10. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
11. Targeting mutant KRAS.
Erlanson DA; Webster KR
Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
[TBL] [Abstract][Full Text] [Related]
12. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
13. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
14. Covalent inhibitors of the GTPase KRAS
Kettle JG; Cassar DJ
Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776
[No Abstract] [Full Text] [Related]
15. Identification of the Clinical Development Candidate
Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
[TBL] [Abstract][Full Text] [Related]
16. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
[TBL] [Abstract][Full Text] [Related]
18. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
19. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
20. The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRAS
Pinnelli M; Trusolino L
Cancer Discov; 2021 Aug; 11(8):1874-1876. PubMed ID: 34344756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
